RT Journal Article
SR Electronic
T1 FKBPL and Peptide Derivatives: Novel Biological Agents That Inhibit Angiogenesis by a CD44-Dependent Mechanism
JF Clinical Cancer Research
JO Clin Cancer Res
FD American Association for Cancer Research
SP 1044
OP 1056
DO 10.1158/1078-0432.CCR-10-2241
VO 17
IS 5
A1 Valentine, Andrea
A1 O'Rourke, Martin
A1 Yakkundi, Anita
A1 Worthington, Jenny
A1 Hookham, Michelle
A1 Bicknell, Roy
A1 McCarthy, Helen O.
A1 McClelland, Keeva
A1 McCallum, Lynn
A1 Dyer, Hayder
A1 McKeen, Hayley
A1 Waugh, David J. J.
A1 Roberts, Jennifer
A1 McGregor, Joanne
A1 Cotton, Graham
A1 James, Iain
A1 Harrison, Timothy
A1 Hirst, David G.
A1 Robson, Tracy
YR 2011
UL http://clincancerres.aacrjournals.org/content/17/5/1044.abstract
AB Purpose: Antiangiogenic therapies can be an important adjunct to the management of many malignancies. Here we investigated a novel protein, FKBPL, and peptide derivative for their antiangiogenic activity and mechanism of action. Experimental Design: Recombinant FKBPL (rFKBPL) and its peptide derivative were assessed in a range of human microvascular endothelial cell (HMEC-1) assays in vitro. Their ability to inhibit proliferation, migration, and Matrigel-dependent tubule formation was determined. They were further evaluated in an ex vivo rat model of neovascularization and in two in vivo mouse models of angiogenesis, that is, the sponge implantation and the intravital microscopy models. Antitumor efficacy was determined in two human tumor xenograft models grown in severe compromised immunodeficient (SCID) mice. Finally, the dependence of peptide on CD44 was determined using a CD44-targeted siRNA approach or in cell lines of differing CD44 status. Results: rFKBPL inhibited endothelial cell migration, tubule formation, and microvessel formation in vitro and in vivo. The region responsible for FKBPL's antiangiogenic activity was identified, and a 24-amino acid peptide (AD-01) spanning this sequence was synthesized. It was potently antiangiogenic and inhibited growth in two human tumor xenograft models (DU145 and MDA-231) when administered systemically, either on its own or in combination with docetaxel. The antiangiogenic activity of FKBPL and AD-01 was dependent on the cell-surface receptor CD44, and signaling downstream of this receptor promoted an antimigratory phenotype. Conclusion: FKBPL and its peptide derivative AD-01 have potent antiangiogenic activity. Thus, these agents offer the potential of an attractive new approach to antiangiogenic therapy. Clin Cancer Res; 17(5); 1044–56. ©2011 AACR. This article is featured in Highlights of This Issue, p. 947